ProKidney (PROK) Stock Price, News & Analysis

Company Overview

ProKidney Corp. (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney disease. The company’s approach is designed to support kidney function and potentially delay or reduce the need for dialysis or kidney transplantation in patients with progressive kidney disease.

Its lead product candidate, rilparencel, is an autologous renal cell therapy made from a patient’s own kidney cells. The cells are processed and administered back into the patient’s kidneys, where they are intended to promote the production of proteins and other factors associated with kidney health. ProKidney is evaluating rilparencel in clinical studies involving patients with diabetic kidney disease and other forms of chronic kidney disease.

ProKidney was founded in 2015 and became a publicly traded company in 2022 through a business combination with Social Capital Suvretta Holdings Corp. III. The company is headquartered in Winston-Salem, North Carolina, and its clinical development activities have primarily focused on patients and research sites in the United States.

Key Stats

• Today's Range: $1.31 to $1.47
• 50-Day Range: $1.33 to $2.01
• 52-Week Range: $1.30 to $3.48
• Volume: 1.66 million shs
• Average Volume: 1.72 million shs
• Market Capitalization: $402.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

ProKidney Stock Analysis - MarketRank™

ProKidney scored higher than 34% of companies evaluated by MarketBeat, and ranked 757th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

ProKidney has a consensus price target of $12.00, representing about 802.3% upside from its current price of $1.33.

Amount of Analyst Coverage

ProKidney has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ProKidney are expected to decrease in the coming year, from ($0.51) to ($0.69) per share.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.08% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 10.97, which indicates bearish sentiment.

Change versus previous month

Short interest in ProKidney has recently increased by 10.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProKidney does not currently pay a dividend.

Dividend Growth

ProKidney does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.61

News Sentiment

ProKidney has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for ProKidney this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,067,315.00 in company stock.

Percentage Held by Insiders

39.83% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PROK
• CIK: 1850270
• Web: www.prokidney.com
• Phone: 336-999-7028
• Fax: N/A
• Employees: 231
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ProKidney: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +802.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.99 million
• Net Margins: -10,288.39%
• Pretax Margin: -20,388.38%
• Return on Equity: N/A
• Return on Assets: -27.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.36
• Quick Ratio: 8.36

Sales & Book Value

• Annual Sales: $890 thousand
• Price / Sales: 451.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.36) per share
• Price / Book: -0.40

Miscellaneous

• Outstanding Shares: 302,320,000
• Free Float: 181,908,000
• Market Cap: $402.09 million
• Optionable: Optionable
• Beta: 1.77